Pharma R&D is increasingly costly and the industry is looking to AI for productivity and ROI improvements. A critical bottleneck in early stage R&D is insight discovery. Huge amounts of researcher time is spent interrogating the literature to find biological connections and uncover new insights, Elsevier has a history of deploying AI to transform these tasks. Guy and Ivana will take you through recent innovations in this space as well as some of the key lessons we have learned.
Speakers
Ivana Kotevic is Vice President of Product, for Corporate Life Sciences at Elsevier, a portfolio that spans from drug discovery and development to pharmacovigilance, leading the group for last 3,5 years. Ivana has a keen interest in leveraging cutting edge technology together with uniquely broad and deep data assets to enable our customers to bring lifesaving medication to patients faster. She has been part of RELX team for 15 years and holds a PhD in Pharmacology.
Guy Kingham is a Senior Director, leading strategy for Elsevier’s Life Sciences business. He has a particular focus on deploying AI across the Elsevier portfolio to help customers with some of the most complex problems drug discovery. He has worked in life sciences strategy for over a decade and holds a PhD in Cancer Biology.